.Pharmacolibrary.Drugs.ATC.V.V03AF12 .Pharmacolibrary.Drugs.ATC.V.V03AF12| name: | Trilaciclib |
| ATC code: | V03AF12 | route: | intravenous |
| n-compartments | 2 |
Trilaciclib is an intravenously administered, selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used to reduce the frequency and severity of chemotherapy-induced myelosuppression in adults receiving certain chemotherapeutic regimens for extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is FDA-approved for this indication. It is not used as an anticancer agent directly, but as a myeloprotective agent to help patients tolerate myelosuppressive chemotherapy.
Population pharmacokinetic model for adult cancer patients (predominantly ES-SCLC) receiving intravenous trilaciclib; parameters from first-in-human, phase 2, and phase 3 studies.
Li, C, et al., & Beelen, A (2023). Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer. British journal of clinical pharmacology 89(3) 1067–1079. DOI:10.1111/bcp.15549 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36180417
Cheng, Y, et al., & Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung cancer (Amsterdam, Netherlands) 188 107455–None. DOI:10.1016/j.lungcan.2023.107455 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38224653
Li, C, et al., & Marbury, TC (2024). Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics. Journal of clinical pharmacology 64(8) 975–983. DOI:10.1002/jcph.2435 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38639103